x
SOON
Abante
ISIN: LU1894892261
Lipper Rating

Abante Biotech Fund C EUR

Fund by Abante

Abante Biotech Fund C EUR

Fund strategy

The investment objective of this Sub-fund is to preserve capital and achieve long-term capital growth primarily by investing mainly throughout the biotechnology sector and in particular within the generic pharmaceuticals, large pharmaceuticals and specialty pharmaceuticals sub-sectors, across geographies and market capitalisations. North America, Nasdaq and small and mid-capitalized companies will be respectively the main geography, market and capitalisation focus of the Sub-Fund.

Performance

January
2022
February
2022
March
2022
April
2022
May
2022
June
2022
July
2022
Asset Manager
Abante Asesores Gestion
Last net asset value
(2022-07-28)
8.26 EUR
Total Returns 1 Year
-17,32 % up
Lipper Risk
-
Category
Equity
Minimum Subscription Amount
not available

Fees and Expenses

Management
1.67%
On the fund size and/or the fund's yield. There may be other expenses associated

Total Returns

Daily
0,98%
up
Week
-2,36%
up
Month
10,28%
up
3 Months
8,68%
up
6 Months
7,41%
up
12 Months
-17,32%
up

Fund's details

Fund Size
Currency
Asset Manager's name
Issue date
14.000.000 EUR
EUR
Armando Cuesta, Juan Martinez
2018-11-30

Geographical Distribution

Fund's portfolio distribution among the different geographical areas.

United States of America 78,99%
SWITZERLAND 6,46%
ISRAEL 1,58%

By investments

Fund's investments distribution.

Editas Medicine Inc Ord 7,05%
Crispr Therapeutics Ag Ord 6,46%
Ardelyx Inc Ord 5,49%
Intuitive Surgical Inc Ord 4,79%
Arcutis Biotherapeutics Inc Ord 4,77%
Phathom Pharmaceuticals Inc Ord 4,72%
Personalis Inc Ord 4,72%
Nanostring Technologies Inc Ord 4,26%
Scpharmaceuticals Inc Ord 4,24%
89bio Inc Ord 4,21%

By sector

Fund's possitions distribution by the sdctor they belong to.

Healthcare 87,04%
Non Classified Equity 0,31%
All data shown on Mercafondos, unless noted otherwise is RDP Lipper by Refinitiv 2022. The information contained herein: (1) is proprietary to Refinitiv and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Refinitiv nor Mercafondos nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results. Refinitiv is one of the world's largest financial market infrastructure and data providers. With more than 40,000 clients and 400,000 users in 190 countries. https://www.refinitiv.com.
x